RxDoctor Payments Data

Julie Bauman

Hematology & Oncology · Washington, DCNPI 1164431748

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Janssen Research & Development, LLC at 57.1% of the total. Reporting peaked in 2024 at $1,826 and has fallen 85.2% since, to $271 in 2025. That places this record below the midpoint for hematology & oncology clinicians in DC, where the typical reported total is $4,025.

$2,471in general payments, 2019–2025

Across 12 payments — averaging $205.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1K
  • AVEO Pharmaceuticals, Inc.$658
  • Gilead$192
  • GT Medical Technologies, Inc$125
  • Modernatx, Inc.$56
  • Daiichi Sankyo Inc.$29
$3,400,120in research payments, 2019–2025

Across 193 payments — averaging $17,617 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$1.7M
  • E.r. Squibb & Sons, L.L.C.$397K
  • Genentech, Inc.$337K
  • Modernatx, Inc.$332K
  • AstraZeneca$287K
  • AVEO Pharmaceuticals, Inc.$156K
  • plus $178K from 4 others

What the payments were for

  • Consulting fees$1,41057%
  • Travel & lodging$472%
  • Food & beverage$1,01441%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,471 in reported general payments places this provider in the 40th percentile of 69 hematology & oncology providers in District of Columbia.

See all hematology & oncology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$291,037
Medicare patients
58
Services billed
13,423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →